Equine Urticaria Treatment via eIL-5 Antigen Immunization
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Chronic recurrent urticaria in horses is challenging to manage due to the difficulty in identifying underlying causes and the recurrence of urticaria episodes, with existing treatments often leading to side effects and inadequate long-term solutions.
Innovation Solution
A composition comprising a core particle with an equine Interleukin-5 antigen linked via a non-peptide covalent bond, administered to prevent or treat recurrent urticaria in horses, which induces immune response and reduces eosinophil levels and urticaria activity.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If existing treatments (systemic steroids) are used to treat urticaria, then acute signs are relieved, but severe side effects occur such as osteoporosis and laminitis
Solution Approach 1:
The patent extracts and targets the specific pathological mechanism of urticaria (mast cell degranulation and eosinophil involvement) by using eIL-5 antigen to specifically inhibit eosinophil recruitment and activation, rather than using broad-spectrum steroids that affect multiple systems and cause side effects
Solution Approach 2:
The patent converts the harmful effect of eosinophils (which contribute to urticaria pathology) into a beneficial target for specific immunomodulation, using eIL-5 to specifically regulate eosinophil activity without affecting other blood cells or causing systemic side effects
2Reliability
If conventional treatments are used for recurrent urticaria, then short-term relief is achieved, but recurrences are common and long-term management is frustrating
Solution Approach 1:
The patent applies preliminary action by using vaccination with eIL-5 antigen to establish long-term immunological memory and sustained immune regulation before urticaria episodes occur, providing preventive long-term protection rather than just treating acute episodes
Solution Approach 2:
The patent establishes a feedback mechanism where the vaccinated immune system continuously monitors and regulates eosinophil activity, adjusting the immune response to maintain long-term remission and prevent recurrence of urticaria
3Ease of operation
If the underlying cause of urticaria is not identified, then treatment is frustrating and recurrences are common, but identification of the underlying cause is challenging
Solution Approach 1:
The patent uses eIL-5 antigen as an intermediary that targets the common pathological pathway (eosinophil-mediated mast cell degranulation) shared by various urticaria causes, effectively treating different etiologies through a unified mechanism without requiring precise identification of the specific trigger
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The composition effectively prevents and treats recurrent urticaria in horses by inducing a strong immune response and significantly reducing eosinophil levels and urticaria activity, as demonstrated by clinical trials where horses showed no signs of urticaria after vaccination.
Implementation Method 1
induces immune response and reduces eosinophil levels and urticaria activity
Data Source
AI summary
The present invention relates to compositions, immunogenic or vaccine compositions and pharmaceutical compositions for the prevention or treatment of urticaria of equine mammals, preferably of horses. Furthermore, the invention provides methods for preventing or treating urticaria of equine mammals, preferably of horses.